Home Multimedia Multimedia Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AML Friday, July 22, 2016 Daniel Pollyea, MD, shares results from an early, phase Ib study of venetoclax plus decitabine or azacitidine in older patients with treatment-naïve acute myeloid leukemia. Advertisement Recent Articles Amgen and Other Drug Makers Drop Discounts for Low-Income Hospitals and Clinics Monday, December 20, 2021 As of January 3, 2022, Amgen will no longer offer discounts on certain drugs to pharmacies used by hospitals and clinics serving low-income populations.... American Cancer Society Publishes 2021 U.S. Cancer Disparities Report Monday, December 20, 2021 American Cancer Society researchers led by Farhad Islami, MD, PhD, released a report on the status of cancer disparities in the U.S. in 2021. The... Former FDA Commissioner to Head Cancer Detection Technology Company Monday, December 20, 2021 Former U.S. Food and Drug Administration (FDA) commissioner Stephen Hahn, MD, will lead Harbinger Health, a company aimed at using artificial intelligence and machine... Study Finds Women Physicians Earn $2M Less Than Male Colleagues Over a 40-Year Career Monday, December 20, 2021 A study published in Health Affairs found that women doctors earn an estimated two million less than their male colleagues over the course of... AHA and AMA Sue U.S. Government Over Provision in Surprise Billing Rule Monday, December 20, 2021 On behalf of hospitals, health systems, and physicians, the American Hospital Association (AHA) and the American Medical Association (AMA) have filed a lawsuit against... Current Issue December 2021 Volume 7 Issue 15 Wednesday, December 1, 2021 This issue explores doctor deserts, celebrates the 50th anniversary of the National Cancer Act, and more.